Protagonist Therapeutics, Inc. announced the appointment of Newman Yeilding, M.D., to the role of Executive Vice President, Chief Scientific Officer. This key leadership addition was effective January 2, 2025.
Dr. Yeilding received inducement awards in accordance with the terms of his employment offer letter on January 2, 2025. His appointment is expected to strengthen the company's scientific leadership and drive its research and development initiatives.
The Chief Scientific Officer plays a crucial role in shaping the company's long-term scientific strategy and advancing its pipeline of peptide-based therapeutics. This executive appointment is a strategic move to enhance Protagonist's innovation capabilities.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.